Incb062079
WebOvarian Cancer - A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular WebAn Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies. Latest version (submitted July 13, 2024) on ClinicalTrials.gov. A study version is represented by a row in the table. Select two study versions to compare. One each from columns A and B.
Incb062079
Did you know?
WebAn Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Additional contact information Cancer … WebA Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Status: Discontinued. Phase of Trial: Phase I/II Latest Information Update: 05 Nov 2024. Price : $35 * Buy Profile. Adis is an information provider. ...
WebINCB062079 also inhibits growth in several tumor models driven by aberrant FGF19 or FGFR4 signaling at tolerated doses in preclinical studies . Based on these preclinical and early-stage clinical data and because of the unmet treatment needs of patients with advanced solid tumors, a first-in-human study of INCB062079 was conducted in this ... WebFind technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes links to find associated …
WebMay 5, 2024 · The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced … WebFirst-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors Journal Article
WebJul 1, 2024 · We describe the preclinical characterization of INCB062079 a potent and selective inhibitor of the FGFR4 kinase. In biochemical assays INCB062079 inhibited …
WebTherapy Detail. Therapy Name. INCB062079. Synonyms. Therapy Description. INCB062079 is a selective FGFR4 inhibitor that prevents tumor cell proliferation in cells with amplification and overexpression of FGF19 (AACR; Cancer Res 2024;77 (13 Suppl):Abstract nr 1234, PMID: 32154250 ). Drugs 1. hellas direct pareriWebDec 25, 2014 · The primary objectives of this study were in 2 parts: Phase l & Phase II. The study included different periods starting by molecular pre-screening (applicable for all subjects enrolled under protocol versions 00 to 03, or applicable only for Phase I and Group 3 in Phase II of FGF401 single agent, for subjects enrolled under protocol version 04), … hellas direct κουπονιWebFind technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes links to find associated clinical trials. hellas direct προσφοραWebMay 5, 2024 · Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs) Time Frame : Baseline to 30-35 days after end of treatment, up to approximately 6 months per subject. An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that … lakeland pharmacy in willow springs moWebThe purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular … lakeland pharmacy crane missouriWebIncb062079 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating incb062079, 1 is phase 1 (0 open). FGF19 Amplification, FGF19 … lakeland pharmacy lakeland flWebJul 1, 2024 · In summary these data demonstrate that INCB062079 is highly and selectively efficacious in models of HCC with FGF19-FGFR4 oncogene addiction and elicits … lakeland pharmacy cumming ga